CENTOGENE GmbH Rostock
58
0
1
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
56.9%
33 terminated/withdrawn out of 58 trials
38.9%
-47.6% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (58)
Rostock International Parkinson's Disease Study (ROPAD)
Role: lead
Epidemiological Study in FRONtoTemporal Dementia
Role: lead
TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Role: lead
Omics Gaucher Study: Multiomic Approach
Role: lead
Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals
Role: lead
Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease
Role: lead
Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
Role: lead
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)
Role: lead
Biomarker for Gilbert Disease (BioGilbert)
Role: lead
Biomarker for Patients With Fabry Disease (BioFabry)
Role: lead
Biomarker for Hurler Disease (BioHurler)
Role: lead
Biomarker for Sly Disease (MPS VII) (BioSly)
Role: lead
Biomarker for Krabbe Disease (BioKrabbe)
Role: lead
Biomarker for Hypophosphatasia Disease (BioHypophos)
Role: lead
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)
Role: lead
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)
Role: lead
Biomarker for Maroteaux-Lamy Disease (BioMaroteaux)
Role: lead
Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)
Role: lead
Biomarker for Niemann Pick Type C Disease (BioNPC)
Role: lead
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
Role: lead